- Joined
- Nov 18, 2014
- Messages
- 227
I wasn't going to write anything more on this topic, but the pharma vs. generic debate will be immortal 
(This post is based on my own professional experience in biopharma, personal experience with various GH, and used AI to compile it all — but only using scientific publications and referenced sources (which are listed at the end))
There will always be those who feel a difference, especially the mythical difference in IGF-1 levels at a lower pharma dose compared to a generic one. And this is justified and entirely possible, despite a theoretically pure raw material according to an HPLC test—and even then, the type of HPLC test is a critical question. It's just like with estrogen testing... but there are many more aspects here.
We will never know for sure, because:
I happen to be one of those who noticed a huge difference in effects, particularly in the dose-to-IGF-1-level ratio, with an overwhelming advantage in favor of Genotropin, which I used to get myself from a pharmacy. For years now, I've been using a trusted generic because I no longer have the ability to arrange a prescription.
The fundamental difference between, for example, Genotropin and generics lies in the technology and method of production.
Pharmaceutical manufacturers primarily choose CHO (Chinese Hamster Ovary) cells for hormone expression because they are mammalian cells. They are capable of creating complex proteins that are nearly identical to human ones. This ensures maximum efficacy, stability, and most importantly, safety, which is an absolute requirement for obtaining marketing authorization from regulatory agencies (like the FDA or EMA). This process is expensive, slow, and complex.
"Underground" labs use E. coli bacteria because it's a cheaper system, but it has one major drawback: the necessity of protein refolding. This is one of the biggest disadvantages and technical challenges of producing in E. coli and is a key differentiator from production in CHO cells.
When E. coli bacteria are instructed to produce a human protein in huge quantities and at breakneck speed, something undesirable happens. In an environment that is foreign to it (the bacterial cell) and with such intense production, the protein cannot correctly fold into its active, three-dimensional structure. Instead, the tangled protein chains stick together, forming inclusion bodies—dense, insoluble, and biologically inactive clumps. At this point, 100% of the produced protein is completely useless.
To recover anything of value from them, producers must conduct a multi-step, chemical refolding process:
In CHO cells, this problem practically doesn't exist. As mammalian cells, they possess the entire machinery for correct protein folding and secrete a finished, correctly folded, and fully active product. This eliminates the need for the complicated and risky refolding process, ensuring much higher quality and safety of the final drug.
Let's go further...
The action of GH is not merely about its presence in the body, but about its precise "fit" into specific receptors on the surface of target cells, like a key in a lock. This fit initiates a cascade of signals inside the cell, leading to a biological effect (e.g., tissue growth). The key to this fit is the correct three-dimensional (3D) structure of the protein, also known as its conformation. We can have 1 gram of a substance that consists 100% of molecules with the correct amino acid sequence (primary structure), but if they are not correctly folded in space, the "key" will not fit the "lock."
Quality control in pharmaceutical production is not just about HPLC—EVEN THOUGH MAMMALIAN CELLS PRODUCE A FULLY FINISHED AND FUNCTIONAL PROTEIN, ELIMINATING THE NEED FOR A REFOLDING STEP.
The main factors determining the functionality of synthetic growth hormone are:
Correct Folding: This is the most important factor. The production process must be optimized so that the newly formed amino acid chain folds into a precise, biologically active 3D structure. An incorrectly folded protein is useless.
Absence of Aggregation: Incorrectly folded molecules tend to clump together into larger complexes called aggregates. Such aggregated hormone is not only non-functional (the receptors are blocked) but can also be harmful, triggering an undesirable immune response.
Correct Isoform: In the human body, growth hormone exists in several variants (isoforms). The main and most active one is the 22-kDa molecule. Synthetic preparations must mimic this specific form. The presence of other, less active isoforms reduces the overall functionality of the product.
Post-Translational Modifications (PTMs): Natural human proteins often undergo additional modifications after synthesis. In the case of growth hormone produced in bacteria, these modifications are absent, which is actually desired. However, production errors, such as the oxidation of certain amino acids (methionine), can destroy the molecule's biological activity.
How is functionality checked? (Quality Control)
Physicochemical Methods:
Chromatography (e.g., HPLC): Checks the purity of the preparation and detects the presence of aggregates or protein fragments.
Electrophoresis (e.g., SDS-PAGE): Verifies if the protein has the correct molecular weight (e.g., 22 kDa).
Spectroscopic Techniques (e.g., Circular Dichroism): Directly analyze the secondary and tertiary structure, i.e., the correctness of the "folding."
Biological Assays (Bioassays):This is the ultimate proof of functionality.
Different types of HPLC: HPLC is not a single technique. For protein analysis, two main types are used:
Reverse-Phase HPLC (RP-HPLC): Separates molecules based on their hydrophobicity (aversion to water). Incorrect protein folding almost always exposes hydrophobic fragments on the outside that are normally hidden inside. Such a misfolded molecule will interact more strongly with the chromatography column and will appear in a different place on the chromatogram (usually later) than the correctly folded hormone.
Size-Exclusion HPLC (SEC-HPLC): Separates molecules based on their size. A correctly folded hormone has a specific, compact size. Misfolded molecules tend to form aggregates (clumps), which are much larger. SEC-HPLC is extremely effective at detecting these aggregates—they will appear on the chromatogram as separate, earlier peaks, clearly indicating product contamination.
Conclusion: If a simple, low-resolution HPLC method were used, it is theoretically possible that minor folding changes would not be detected. However, professional drug quality control uses validated, high-resolution methods (often both RP- and SEC-HPLC) that are designed specifically to detect such abnormalities. In this case, a misfolded or aggregated hormone would be identified as an impurity, not a pure product.
Part 2 below
(This post is based on my own professional experience in biopharma, personal experience with various GH, and used AI to compile it all — but only using scientific publications and referenced sources (which are listed at the end))
There will always be those who feel a difference, especially the mythical difference in IGF-1 levels at a lower pharma dose compared to a generic one. And this is justified and entirely possible, despite a theoretically pure raw material according to an HPLC test—and even then, the type of HPLC test is a critical question. It's just like with estrogen testing... but there are many more aspects here.
We will never know for sure, because:
- No one will conduct clinical trials and in-depth raw material analysis (which involves much more than just HPLC) on generics.
- Every batch of a generic can differ. There's a lot that can go wrong in the process, and it lacks the quality standards of pharma. This isn't about the equipment, but about meticulously controlled procedures and processes. There's a lack of the analytical tools required by pharma to manage this quality.
- Everyone shares their own empirical experiences. Unfortunately, for me, if someone hasn't personally picked up GH from a pharmacy with a prescription—where even the transport and storage procedures are strictly monitored—then such comparisons are meaningless. "Pharma" from the black market is just another generic.
I happen to be one of those who noticed a huge difference in effects, particularly in the dose-to-IGF-1-level ratio, with an overwhelming advantage in favor of Genotropin, which I used to get myself from a pharmacy. For years now, I've been using a trusted generic because I no longer have the ability to arrange a prescription.
The fundamental difference between, for example, Genotropin and generics lies in the technology and method of production.
Pharmaceutical manufacturers primarily choose CHO (Chinese Hamster Ovary) cells for hormone expression because they are mammalian cells. They are capable of creating complex proteins that are nearly identical to human ones. This ensures maximum efficacy, stability, and most importantly, safety, which is an absolute requirement for obtaining marketing authorization from regulatory agencies (like the FDA or EMA). This process is expensive, slow, and complex.
"Underground" labs use E. coli bacteria because it's a cheaper system, but it has one major drawback: the necessity of protein refolding. This is one of the biggest disadvantages and technical challenges of producing in E. coli and is a key differentiator from production in CHO cells.
When E. coli bacteria are instructed to produce a human protein in huge quantities and at breakneck speed, something undesirable happens. In an environment that is foreign to it (the bacterial cell) and with such intense production, the protein cannot correctly fold into its active, three-dimensional structure. Instead, the tangled protein chains stick together, forming inclusion bodies—dense, insoluble, and biologically inactive clumps. At this point, 100% of the produced protein is completely useless.
To recover anything of value from them, producers must conduct a multi-step, chemical refolding process:
- Isolation and Denaturation: First, the bacterial cells are broken open, and these hard "clumps" of protein are isolated. Then, they are dissolved in strong chemicals (denaturants, e.g., concentrated urea), which completely "unravel" all the tangled protein chains.
- Refolding: This is the most critical and difficult stage. By slowly and controllably removing the denaturant, conditions are created in which the "unraveled" protein chains have a chance to spontaneously fold anew—this time, into the correct, active form.
In CHO cells, this problem practically doesn't exist. As mammalian cells, they possess the entire machinery for correct protein folding and secrete a finished, correctly folded, and fully active product. This eliminates the need for the complicated and risky refolding process, ensuring much higher quality and safety of the final drug.
Let's go further...
The action of GH is not merely about its presence in the body, but about its precise "fit" into specific receptors on the surface of target cells, like a key in a lock. This fit initiates a cascade of signals inside the cell, leading to a biological effect (e.g., tissue growth). The key to this fit is the correct three-dimensional (3D) structure of the protein, also known as its conformation. We can have 1 gram of a substance that consists 100% of molecules with the correct amino acid sequence (primary structure), but if they are not correctly folded in space, the "key" will not fit the "lock."
Quality control in pharmaceutical production is not just about HPLC—EVEN THOUGH MAMMALIAN CELLS PRODUCE A FULLY FINISHED AND FUNCTIONAL PROTEIN, ELIMINATING THE NEED FOR A REFOLDING STEP.
The main factors determining the functionality of synthetic growth hormone are:
Correct Folding: This is the most important factor. The production process must be optimized so that the newly formed amino acid chain folds into a precise, biologically active 3D structure. An incorrectly folded protein is useless.
Absence of Aggregation: Incorrectly folded molecules tend to clump together into larger complexes called aggregates. Such aggregated hormone is not only non-functional (the receptors are blocked) but can also be harmful, triggering an undesirable immune response.
Correct Isoform: In the human body, growth hormone exists in several variants (isoforms). The main and most active one is the 22-kDa molecule. Synthetic preparations must mimic this specific form. The presence of other, less active isoforms reduces the overall functionality of the product.
Post-Translational Modifications (PTMs): Natural human proteins often undergo additional modifications after synthesis. In the case of growth hormone produced in bacteria, these modifications are absent, which is actually desired. However, production errors, such as the oxidation of certain amino acids (methionine), can destroy the molecule's biological activity.
How is functionality checked? (Quality Control)
Physicochemical Methods:
Chromatography (e.g., HPLC): Checks the purity of the preparation and detects the presence of aggregates or protein fragments.
Electrophoresis (e.g., SDS-PAGE): Verifies if the protein has the correct molecular weight (e.g., 22 kDa).
Spectroscopic Techniques (e.g., Circular Dichroism): Directly analyze the secondary and tertiary structure, i.e., the correctness of the "folding."
Biological Assays (Bioassays):This is the ultimate proof of functionality.
- In vitro (in the lab): The hormone preparation is added to a cell culture that has growth hormone receptors. The response of these cells, such as their proliferation, is then measured. This is a direct test of the "key's" ability to open the "lock."
- In vivo (in the body): Although this is the domain of clinical trials rather than routine batch control, it is tests on patients (e.g., IGF-1 stimulation tests) that ultimately confirm the drug works as expected.
Different types of HPLC: HPLC is not a single technique. For protein analysis, two main types are used:
Reverse-Phase HPLC (RP-HPLC): Separates molecules based on their hydrophobicity (aversion to water). Incorrect protein folding almost always exposes hydrophobic fragments on the outside that are normally hidden inside. Such a misfolded molecule will interact more strongly with the chromatography column and will appear in a different place on the chromatogram (usually later) than the correctly folded hormone.
Size-Exclusion HPLC (SEC-HPLC): Separates molecules based on their size. A correctly folded hormone has a specific, compact size. Misfolded molecules tend to form aggregates (clumps), which are much larger. SEC-HPLC is extremely effective at detecting these aggregates—they will appear on the chromatogram as separate, earlier peaks, clearly indicating product contamination.
Conclusion: If a simple, low-resolution HPLC method were used, it is theoretically possible that minor folding changes would not be detected. However, professional drug quality control uses validated, high-resolution methods (often both RP- and SEC-HPLC) that are designed specifically to detect such abnormalities. In this case, a misfolded or aggregated hormone would be identified as an impurity, not a pure product.
Part 2 below
